Cargando…

The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment

BACKGROUND: Escherichia coli (E. coli) is a common pathogen in bloodstream infections (BSI), and the production of extended-spectrum beta-lactamases (ESBLs) is its main mechanism of resistance. However, the impact of different ESBL genotypes of E. coli on the resistance to Cefepime (FEP) remains unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qian, Shi, Jing, Huang, Juan, Gan, Delu, Zhang, Lijun, Li, Pu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544110/
https://www.ncbi.nlm.nih.gov/pubmed/37789844
http://dx.doi.org/10.2147/IDR.S427836
_version_ 1785114432562528256
author Wu, Qian
Shi, Jing
Huang, Juan
Gan, Delu
Zhang, Lijun
Li, Pu
author_facet Wu, Qian
Shi, Jing
Huang, Juan
Gan, Delu
Zhang, Lijun
Li, Pu
author_sort Wu, Qian
collection PubMed
description BACKGROUND: Escherichia coli (E. coli) is a common pathogen in bloodstream infections (BSI), and the production of extended-spectrum beta-lactamases (ESBLs) is its main mechanism of resistance. However, the impact of different ESBL genotypes of E. coli on the resistance to Cefepime (FEP) remains unclear. METHODS: A total of 2356 cases of BSI patients were collected. The experimental group included 188 ESBL-positive E. coli strains that were resistant to FEP but sensitive to ceftazidime (CAZ). Antibiotic usage and resistance rates were evaluated through antimicrobial susceptibility testing and antibiotic usage records. The ESBL genotypes were identified, and the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of FEP were determined. RESULTS: In ESBL-positive E. coli, three ESBL genotypes were identified: 188 strains of CTX-M, 130 strains of TEM-1, and 26 strains of OXA-10. Among them, 124 strains carried both CTX-M-9 and TEM-1 genotypes, 22 strains carried two CTX-M genotypes (CTX-M-1 and CTX-M-2), 20 strains carried both CTX-M-9 and OXA-10, and 6 strains carried three genotypes (CTX-M-9, CTX-TEM-1, and OXA-10). The MIC50, MIC90, MPC50, and MPC90 of the 188 ESBL-positive E. coli were 64, 256, 128, and 528, respectively. The MIC values ranged from 32 to 256, while the MPC values ranged from 64 to 528. The MIC50, MIC90, MPC50, and MPC90 of the 40 ESBL-negative E. coli were 0.5, 1, 64, and 128, respectively; the MIC values ranged from 0.25 to 4, while the MPC values ranged from 32 to 256, respectively. CONCLUSION: ESBL-positive E. coli induces an increase in the MIC value of FEP, leading to an increase in FEP resistance. The inoculation effect also causes a significant increase in the MPC value of FEP, especially the increase in selection index value, indicating selective enrichment and amplification of drug-resistant mutants, resulting in clinical treatment failure.
format Online
Article
Text
id pubmed-10544110
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105441102023-10-03 The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment Wu, Qian Shi, Jing Huang, Juan Gan, Delu Zhang, Lijun Li, Pu Infect Drug Resist Original Research BACKGROUND: Escherichia coli (E. coli) is a common pathogen in bloodstream infections (BSI), and the production of extended-spectrum beta-lactamases (ESBLs) is its main mechanism of resistance. However, the impact of different ESBL genotypes of E. coli on the resistance to Cefepime (FEP) remains unclear. METHODS: A total of 2356 cases of BSI patients were collected. The experimental group included 188 ESBL-positive E. coli strains that were resistant to FEP but sensitive to ceftazidime (CAZ). Antibiotic usage and resistance rates were evaluated through antimicrobial susceptibility testing and antibiotic usage records. The ESBL genotypes were identified, and the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of FEP were determined. RESULTS: In ESBL-positive E. coli, three ESBL genotypes were identified: 188 strains of CTX-M, 130 strains of TEM-1, and 26 strains of OXA-10. Among them, 124 strains carried both CTX-M-9 and TEM-1 genotypes, 22 strains carried two CTX-M genotypes (CTX-M-1 and CTX-M-2), 20 strains carried both CTX-M-9 and OXA-10, and 6 strains carried three genotypes (CTX-M-9, CTX-TEM-1, and OXA-10). The MIC50, MIC90, MPC50, and MPC90 of the 188 ESBL-positive E. coli were 64, 256, 128, and 528, respectively. The MIC values ranged from 32 to 256, while the MPC values ranged from 64 to 528. The MIC50, MIC90, MPC50, and MPC90 of the 40 ESBL-negative E. coli were 0.5, 1, 64, and 128, respectively; the MIC values ranged from 0.25 to 4, while the MPC values ranged from 32 to 256, respectively. CONCLUSION: ESBL-positive E. coli induces an increase in the MIC value of FEP, leading to an increase in FEP resistance. The inoculation effect also causes a significant increase in the MPC value of FEP, especially the increase in selection index value, indicating selective enrichment and amplification of drug-resistant mutants, resulting in clinical treatment failure. Dove 2023-09-27 /pmc/articles/PMC10544110/ /pubmed/37789844 http://dx.doi.org/10.2147/IDR.S427836 Text en © 2023 Wu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wu, Qian
Shi, Jing
Huang, Juan
Gan, Delu
Zhang, Lijun
Li, Pu
The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
title The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
title_full The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
title_fullStr The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
title_full_unstemmed The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
title_short The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
title_sort impact of esbls-positive escherichia coli’s resistance to cefepime and its guidance for clinical treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544110/
https://www.ncbi.nlm.nih.gov/pubmed/37789844
http://dx.doi.org/10.2147/IDR.S427836
work_keys_str_mv AT wuqian theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT shijing theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT huangjuan theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT gandelu theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT zhanglijun theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT lipu theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT wuqian impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT shijing impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT huangjuan impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT gandelu impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT zhanglijun impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment
AT lipu impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment